Non-Hodgkin lymphoma

Jamés O. Armitage(University of Nebraska Medical Center), Randy D. Gascoyne(BC Cancer Agency), Matthew A. Lunning(University of Nebraska Medical Center), Franco Cavalli(Institute of Oncology Research)

The Lancet

January 31, 2017

10.1016/s0140-6736(16)32407-2

Cited by 1,173

Abstract

Related Papers

Cancer: Principles and Practice of Oncology.

|Annals of Internal Medicine|1991|8.5k

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20

ME Reff, K Carner, KS Chambers et al.|Blood|1994|1.9k

The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells

H Stein, DY Mason, Johannes Gerdes et al.|Blood|1985|1.8k

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

David G. Maloney, Antonio J Grillo-López, Christine A. White et al.|Blood|1997|1.7k

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

Wyndham H. Wilson, Ryan M. Young, Roland Schmitz et al.|Nature Medicine|2015|1.1k